Skip to main content
Log in

Hyperuricemia and cardiovascular risk

  • Review Article
  • Published:
High Blood Pressure & Cardiovascular Prevention Aims and scope Submit manuscript

Abstract

There is an increasing prevalence of gout and hyperuricemia worldwide. Gout confers a significant individual and social burden and is increasingly recognized as a prevalent chronic disease state requiring appropriate long-term management. Gout and hyperuricemia appear to be independent risk factors for incident hypertension, renal disease and cardiovascular disease. Multiple epidemiologic studies confirm an association between hyperuricemia and “cardiometabolic disease”. We review the evidence stating the relationship between hyperuricemia and the development of comorbid conditions contributing to cardiovascular risk and disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Richette P, Bardin T. Gout. Lancet 2010; 375 (9711):318–328.

    Google Scholar 

  2. Choi HK, Mount DB, Reginato AM. Pathogenesis of gout. Ann Intern Med. 2005;143:499–516.

    Article  CAS  PubMed  Google Scholar 

  3. Johnson RJ, Rideout BA. Uric acid and diet-insights into the epidemic of cardiovascular disease. N Engl J Med. 2004;350:1071–3.

    Article  CAS  PubMed  Google Scholar 

  4. Edwards NL. The role of hyperuricemia and gout in kidney and cardiovascular disease. Cleve Clin J Med. 2008;75(Suppl 5):S13–6.

    Article  PubMed  Google Scholar 

  5. Gustafsson D, Unwin R. The pathophysiology of hyperuricaemia and its possible relationship to cardiovascular disease, morbidity and mortality. BMC Nephrol. 2013;14:164.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  6. Wortmann RL. Gout and hyperuricemia. Curr Opin Rheumatol. 2002;14:281–6.

    Article  PubMed  Google Scholar 

  7. Saag KG, Mikuls TR. Recent advances in the epidemiology of gout. Curr Rheumatol Rep. 2005;7:235–41.

    Article  PubMed  Google Scholar 

  8. Grassi D, Ferri L, Desideri G, Di Giosia P, Cheli P, Del Pinto R, Properzi G, Ferri C. Chronic hyperuricemia, uric acid deposit and cardiovascular risk. Curr Pharm Des. 2013;19(13):2432–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S, Tuttle KR, Rodriguez-Iturbe B, Herrera-Acosta J, Mazzali M. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension. 2003;41:1183–90.

    Article  CAS  PubMed  Google Scholar 

  10. Yoo TW, Sung KC, Shin HS, et al. Relationship between serum uric acid concentration and insulin resistance and metabolic syndrome. Circ J. 2005;69:928–33.

    Article  CAS  PubMed  Google Scholar 

  11. Ferri C, Ferri L, Grassi D. Uric acid as a marker and contributor to cardiovascular disease. Cardiol Clin Pract. 2011;3(1):1–11.

    Google Scholar 

  12. Cannon PJ, Stason WB, Demartini FE, Sommers SC, Laragh JH. Hyperuricemia in primary and renal hypertension. N Engl J Med. 1966;275:457–64.

    Article  CAS  PubMed  Google Scholar 

  13. Perlstein TS, Gumieniak O, Williams GH, et al. Uric acid and the development of hypertension: the normative aging study. Hypertension. 2006;48(6):1031–6.

    Article  CAS  PubMed  Google Scholar 

  14. Messerli FH, Frohlich ED, Dreslinski GR, Suarez DH, Aristimuno GG. Serum uric acid in essential hypertension: an indicator of renal vascular involvement. Arch Intern Med. 1980;93:817–21.

    CAS  Google Scholar 

  15. Friedl HP, Smith DJ, Till GO, Thomson PD, Louis DS, Ward PA. Ischemia-reperfusion in humans. Appearance of xanthine oxidase activity. Am J Pathol. 1990;136(3):491–5.

    CAS  PubMed Central  PubMed  Google Scholar 

  16. Ferrannini E, Galvan AQ, Gastaldelli A, Camastra S, Sironi AM, Toschi E, Baldi S, Frascerra S, Monzani F, Antonelli A, Nannipieri M, Mari A, Seghieri G, Natali A. Insulin: new roles for an ancient hormone. Eur J Clin Investig. 1999;29(10):842–52.

    Article  CAS  Google Scholar 

  17. Gonçalves JP, Oliveira A, Severo M, Santos AC, Lopes C. Cross-sectional and longitudinal associations between serum uric acid and metabolic syndrome. Endocrine. 2012;41(3):450–7.

    Article  PubMed  Google Scholar 

  18. Rodrigues SL, Baldo MP, Capingana P, Magalhães P, Dantas EM, Molina Mdel C, Salaroli LB, Morelato RL, Mill JG. Gender distribution of serum uric acid and cardiovascular risk factors: population based study. Arq Bras Cardiol. 2012;98(1):13–21.

    Article  CAS  PubMed  Google Scholar 

  19. Fam AG. Gout, diet, and the insulin resistance syndrome. J Rheumatol. 2002;29:1350–5.

    CAS  PubMed  Google Scholar 

  20. Facchini F, Chen YD, Hollenbeck CB, Reaven GM. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA. 1991;266(21):3008–11.

    Article  CAS  PubMed  Google Scholar 

  21. Dessein PH, Shipton EA, Stanwix AE, Joffe BI, Ramokgadi J. Beneficial effects of weight loss associated with moderate calorie/ carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: a pilot study. Ann Rheum Dis. 2000;59:539–43.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  22. Cicero AF, Salvi P, D’Addato S, Rosticci M, Borghi C, Brisighella Heart Study group. Association between serum uric acid, hypertension, vascular stiffness and subclinical atherosclerosis: data from the Brisighella Heart Study. J Hypertens. 2014;32(1):57–64.

    Article  CAS  PubMed  Google Scholar 

  23. Liese AD, Hense HW, Lowel H, et al. Association of serum acid with all-cause and cardiovascular disease and incident myocardial infarction in the MONICA Augsburg cohort. World Health Organization monitoring trends and determinants in cardiovascular diseases. Epidemiology. 1999;10:391–7.

    Article  CAS  PubMed  Google Scholar 

  24. Hoieggen A, et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int. 2004;65:1041–9.

    Article  CAS  PubMed  Google Scholar 

  25. Bos MJ, Koudstaal PJ, Hofman A, Witteman JCM, Breteker MMB. Uric acid is a risk factor for myocardial infarction and stroke. Stroke. 2006;37:1503–7.

    Article  CAS  PubMed  Google Scholar 

  26. Krishnan E, Baker JF, Furst DE, Schumacher HR. Gout and the risk of acute myocardial infarction. Arthritis Rheum. 2006;54:2688–96.

    Article  CAS  PubMed  Google Scholar 

  27. Brand FN, McGee DL, Kannel WB, Stokes J III, Castelli WP. Hyperuricemia as a risk factor of coronary heart disease: the Framingham Study. Am J Epidemiol. 1985;121:11–8.

    CAS  PubMed  Google Scholar 

  28. Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med. 1999;131:7–13.

    Article  CAS  PubMed  Google Scholar 

  29. Strasak A, Ruttmann E, Brant L, et al. Serum uric acid and risk of cardiovascular mortality: a prospective long-term study of 83683 Austrian men. Clin Chem. 2008;54:273–84.

    Article  CAS  PubMed  Google Scholar 

  30. Loachimescu AG, Brennan DM, Hoar BM, Hazen SL, Hoogwerf BJ. Serum uric acid is an independent predictor of all-cause mortality in patients at high risk of cardiovascular disease: a preventive cardiology information system (PreCIS) database cohort study. Arthritis Rheum. 2008;58(2):623–30.

    Article  Google Scholar 

  31. Verdecchia P, Schillaci G, Reboldi G, et al. Relation between serum uric acid and risk of cardiovascular disease in essential hypertension: the PIUMA study. Hypertension. 2000;36:1072–8.

    Article  CAS  PubMed  Google Scholar 

  32. Kim SY, Guevara JP, Kim KM, et al. Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2010;62(2):170–80.

    Google Scholar 

  33. Kim SY, Guevara JP, Kim KM, et al. Hyperuricemia and risk of stroke: a systematic review and meta-analysis. Arthritis Rheum. 2009;61(7):885–92.

    Article  PubMed Central  PubMed  Google Scholar 

  34. Khosla UM, Zharikov S, Finch JL, et al. Hyperuricemia induces endothelial dysfunction. Kidney Int. 2005;67(5):1739–42.

    Article  PubMed  Google Scholar 

  35. Kanellis J, Kang DH. Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. Semin Nephrol. 2005;25(1):39–42.

    Article  CAS  PubMed  Google Scholar 

  36. Coronel F, Garcıa-Menal M, Herrero JA, et al. Irbesartan in hypertensive non-diabetic advanced chronic kidney disease: comparative study with ACEI. Nefrologia. 2008;28(1):56–60.

    CAS  PubMed  Google Scholar 

  37. Becker MA, Schumacher HR, MacDonald PA, et al. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol. 2009;36(6):1273–82.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Davide Grassi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Grassi, D., Desideri, G., Di Giacomantonio, A.V. et al. Hyperuricemia and cardiovascular risk. High Blood Press Cardiovasc Prev 21, 235–242 (2014). https://doi.org/10.1007/s40292-014-0046-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40292-014-0046-3

Keywords

Navigation